India to Nigeria: Aminophylline Export Trade Route
India has recorded 10 verified shipments of Aminophylline exported to Nigeria, representing a combined trade value of $316.7K USD. This corridor is served by 4 active Indian exporters, with an average shipment value of $31.7K USD. The leading Indian exporter is IMPULSE PHARMA PRIVATE LIMITED, which accounts for 42% of total export value with 2 shipments worth $133.2K USD. On the buying side, SHREE ALOE PHARMACEUTICAL CO LTD is the largest importer in Nigeria with $133.2K USD in purchases. The top 3 suppliers — IMPULSE PHARMA PRIVATE LIMITED, MANCARE PHARMACEUTICALS PRIVATE LIMITED, MANCARE PHARMACEUTICALS PRIVATE LIMITED — together control of total trade value on this route. All data sourced from Indian Customs (DGFT) shipping bill records. Values reported in FOB USD.
Route Intelligence Overview
The India to Nigeria Aminophylline corridor is one of India's established pharmaceutical export routes, with 10 shipments documented worth a combined $316.7K USD. The route is dominated by IMPULSE PHARMA PRIVATE LIMITED, which alone accounts for roughly 42% of all export value, reflecting the consolidated nature of India's aminophylline manufacturing sector.
Across 4 active suppliers, the average shipment value stands at $31.7K USD — a figure that reflects both bulk commercial orders from large pharmaceutical companies and smaller specialty shipments. Freight is split between sea (68%) and air (17%), suggesting a mix of scheduled bulk orders and time-sensitive consignments.
Shipment activity peaks during April–June, with an average transit time of 32 days port-to-port. The route has recorded an annual growth rate of 23.1%, placing it at rank #1 among India's top aminophylline export destinations globally.
On the import side, key buyers of Indian aminophylline in Nigeria include SHREE ALOE PHARMACEUTICAL CO LTD, NKOYO CHEMISTS , APHANTEE PHARM CO NIG LIMITED and 6 others. SHREE ALOE PHARMACEUTICAL CO LTD is the single largest importer with 2 shipments valued at $133.2K USD.
